ENCORE
CompletedA study to define the performance characteristics of the HelioLiver Test within a study population of subjects diagnosed with liver cancer at various stages (I to IV).
Learn how Helio is advancing cancer research through clinical studies and collaborating with partners.
We are proud to collaborate with organisations that share our mission and values. We are currently partnering with leading medical institutions and research centres to advance early cancer detection research.
Helio Genomics
We are dedicated to making accurate early detection tests available for more cancers. Helio is currently engaged in multiple pivotal, multi-centre trials in the US and China.
A study to define the performance characteristics of the HelioLiver Test within a study population of subjects diagnosed with liver cancer at various stages (I to IV).
A multi-centre, prospective study conducted in the US to compare the sensitivity and specificity of the HelioLiver Test with ultrasound within a population at high risk of HCC due to liver cirrhosis.
A prospective R01 study sponsored by the NCI in collaboration with Mount Sinai and other US medical institutions to evaluate novel screening modalities and biomarkers.
A multi-centre, prospective study conducted in the US to discover new biomarkers for various cancer types, including colon, lung, and breast.
A multi-centre, prospective study conducted in the US to develop and validate the Helio Multi-Analyte Blood Test within a population at high risk for HCC due to liver disease or cirrhosis, and in HCC-positive subjects.
Helio is looking to partner with research and clinical organisations that see patients who have cancer or are at high risk of developing it. Leave us a message if you are interested in collaborating with us on upcoming clinical trials and research.